Microvascular and macrovascular complications in children and adolescents

Pediatric Diabetes

Volumn 15, Issue SUPPL.20, 2014, Pages 257-269

  Donaghue, Kim C ^a,b   Wadwa, R Paul ^c   Dimeglio, Linda A ^d   Wong, Tien Y ^e   Chiarelli, Francesco ^f   Marcovecchio, M Loredana ^f   Salem, Mona ^g   Raza, Jamal ^h   Hofman, Paul L ⁱ   Craig, Maria E ^a,b,j  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^f UNIVERSITY OF CHIETI   (Italy)

^g AIN SHAMS UNIVERSITY   (Egypt)

^h NATIONAL INSTITUTE OF CHILD HEALTH   (Pakistan)

ⁱ UNIVERSITY OF AUCKLAND   (New Zealand)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

Child; Complications; Evidence; Guidelines; Type 1 diabetes

Indexed keywords

ADOLESCENT; CHILD; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HUMAN; INFANT; INTERNATIONAL COOPERATION; MEDICINE; MICROVASCULATURE; MULTIMODALITY CANCER THERAPY; PATIENT EDUCATION; PEDIATRICS; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRESCHOOL CHILD; RISK FACTOR; SELF CARE; TRENDS;

ADOLESCENT; ADOLESCENT MEDICINE; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; INFANT; INTERNATIONAL AGENCIES; MICROVESSELS; PATIENT EDUCATION AS TOPIC; PEDIATRICS; RISK FACTORS; SELF CARE; SOCIETIES, SCIENTIFIC;

EID: 84906835030     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12180     Document Type: Article

References (139)

1. DCCT Research Group (Diabetes Control and Complications Trial Research Group). Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994: 125: 177-188.
2. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994: 330: 15-18.
3. Mohsin F et al. Discordant trends in microvascular complications in adolescents with type 1 diabetes from 1990 to 2002. Diabetes Care 2005: 28: 1974-1980.
4. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002: 25: 859-864.
5. Downie E et al. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. Diabetes Care 2011: 34: 2368-2373.
6. Cho YH, Craig ME, Hing S, Gallego PH, Poon M, Chan A, Donaghue KC. Microvascular complications assessment in adolescents with 2- to 5-yr duration of type 1 diabetes from 1990 to 2006. Pediatric Diabetes 2011: 12(8): 682-689.
7. Yau JW et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012: 35(3): 556-564.
8. Wong TY et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009: 32(12): 2307-2313.
9. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010: 376(9735): 124-136.
10. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. Journal of the American Medical Association 2007: 298(8): 902-916.
11. Craig ME et al. Diabetes care, glycemic control, and complications in children with type 1 diabetes from Asia and the Western Pacific Region. J Diabetes Complications 2007: 21: 280-287.
12. Majaliwa ES et al. Survey on acute and chronic complications in children and adolescents with type 1 diabetes at Muhimbili National Hospital in Dar es Salaam, Tanzania. Diabetes Care 2007: 30: 2187-2192.
13. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
14. Nathan DM et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005: 353: 2643-2653.
15. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). The Journal of Pediatrics 2001:139: 804-812.
16. DCCT Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998: 116: 874-886.
17. White NH et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010: 59: 1244-1253.
18. Krolewski AS et al. The changing natural history of nephropathy in type I diabetes. Am J Med 1985: 78: 785-794.
19. Donaghue KC et al. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes Care 2003: 26: 1224-1229.
20. Cho YH, Craig ME, Donaghue KC. Puberty as an accelerator for diabetes complications. Pediatr Diabetes 2014: 15: 18-26.
21. Donaghue KC et al. Prevalence of diabetes complications 6years after diagnosis in an incident cohort of childhood diabetes. Diabet Med 2005: 22: 711-718.
22. Amin R et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 2008: 336: 697-701.
23. Hietala K et al. Age at onset and the risk of proliferative retinopathy in type 1 diabetes. Diabetes Care 2010: 33: 1315-1319.
24. Margeirsdottir HD et al. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. Diabetologia 2008: 51: 554-561.
25. Wood JR et al. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 2013: 36: 2035-2037.
26. Couper JJ et al. Relationship of smoking and albuminuria in children with insulin-dependent diabetes. Diabet Med 1994: 11: 666-669.
27. Gaedt Thorlund M et al. Is smoking a risk factor for proliferative diabetic retinopathy in type 1 diabetes? Ophthalmologica 2013: 230: 50-54.
28. Wong CW et al. Kidney and eye diseases: common risk factors, etiological mechanisms, and pathways. Kidney Int 2014: 85: 1290-1302.
29. Gay EC et al. Smokers with IDDM experience excess morbidity. The Colorado IDDM Registry. Diabetes Care 1992: 15: 947-952.
30. Lurbe E et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002: 347: 797-805.
31. Marcovecchio ML et al. Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. Diabetologia 2009: 52: 1173-1181.
32. Gallego PH et al. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ 2008: 337: a918.
33. Stamler J et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993: 16: 434-444.
34. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998: 351: 1755-1762.
35. Jenkins AJ et al. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 2003: 64: 817-828.
36. Lyons TJ et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004: 45: 910-918.
37. Seaquist ER et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989: 320: 1161-1165.
38. Soergel M et al. Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. J Pediatr 1997: 130: 178-184.
39. Dorchy H, Claes C, Verougstraete C. Risk factors of developing proliferative retinopathy in type 1 diabetic patients: role of BMI. Diabetes Care 2002: 25: 798-799.
40. De Block CE, De Leeuw IH, Van Gaal LF. Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 2005: 28: 1649-1655.
41. Stone ML et al. Natural history and risk factors for microalbuminuria in adolescents with type 1 diabetes: a longitudinal study. Diabetes Care 2006: 29: 2072-2077.
42. Koivisto VA et al. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 1996: 19: 689-697.
43. Rodrigues TC et al. Obesity and coronary artery calcium in diabetes: the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. Diabetes Technol Ther 2011: 13: 991-996.
44. Moy CS et al. Insulin-dependent diabetes mellitus, physical activity, and death. Am J Epidemiol 1993: 137: 74-81.
45. Maguire A et al. The case for biennial retinopathy screening in children and adolescents. Diabetes Care 2005: 28: 509-513.
46. Soffer B et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 2003: 16: 795-800.
47. Maguire A et al. The case for biennial retinopathy screening in children and adolescents: response to Stefansson. Diabetes Care 2006: 29: 178-179.
48. Klein R et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984: 102: 520-526.
49. LeCaire TJ et al. Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 2013: 36: 631-637.
50. Anonymous. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978: 85: 82-106.
51. Mitchell P, Foran S, Wong TY, Chua B, Patel I, Ojaimi E. Guidelines for the Management of Diabetic Retinopathy. National Health and Medical Research Council (Australia): Barton ACT 2008 (available from: https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/di15.pdf).
52. Scanlon PH et al. Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy. Br J Ophthalmol 2003: 87: 1258-1263.
53. Olson JA et al. A comparative evaluation of digital imaging, retinal photography and optometrist examination in screening for diabetic retinopathy. Diabet Med 2003: 20: 528-534.
54. Lin DY et al. The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. Am J Ophthalmol 2002: 134: 204-213.
55. Murgatroyd H et al. Effect of mydriasis and different field strategies on digital image screening of diabetic eye disease. Br J Ophthalmol 2004: 88: 920-924.
56. Bailey CC et al. The national diabetic retinopathy laser treatment audit. III. Clinical outcomes. Eye (Lond) 1999: 13 (Pt 2): 151-159.
57. Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 1996: 94: 505-537.
58. Mogensen CE et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995: 346: 1080-1084.
59. Schultz CJ et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care 1999: 22: 495-502.
60. Groop PH et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009: 58: 1651-1658.
61. Orchard TJ et al. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010: 53: 2312-2319.
62. Twyman S et al. Longitudinal study of urinary albumin excretion in young diabetic patients--Wessex Diabetic Nephropathy Project. Diabet Med 2001: 18: 402-408.
63. Mogensen CE et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995: 346(8982): 1080-1084.
64. Association AD. Standards of medical care in diabetes - 2014. Diabetes Care 2014: 37 (Suppl. 1): S14-S80.
65. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005: 48: 1439-1444.
66. Ruggenenti P, Remuzzi G. Kidney failure stabilizes after a two-decade increase: impact on global (renal and cardiovascular) health. Clin J Am Soc Nephrol 2007: 2: 146-150.
67. Mathiesen ER et al. Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 1984: 26: 406-410.
68. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984: 311: 89-93.
69. Viberti GC et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982: 1: 1430-1432.
70. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985: 28: 590-596.
71. Valdorf-Hansen F et al. Cardiovascular risk factors in type I (insulin-dependent) diabetic patients with and without proteinuria. Acta Med Scand 1987: 222: 439-4.
72. Amin R et al. The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: the Oxford Regional Prospective Study. Kidney Int 2005: 68: 1740-1749.
73. Couper JJ et al. Progression of borderline increases in albuminuria in adolescents with insulin-dependent diabetes mellitus. Diabet Med 1997: 14: 766-771.
74. Lurbe E, Sorof JM, Daniels SR. Clinical and research aspects of ambulatory blood pressure monitoring in children. J Pediatr 2004: 144: 7-16.
75. Perkins BA et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003: 348: 2285-2293.
76. Rudberg S, Dahlquist G. Determinants of progression of microalbuminuria in adolescents with IDDM. Diabetes Care 1996: 19: 369-371.
77. Zerbini G et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes 2006: 55: 2620-2625.
78. Finne P et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005: 294: 1782-1787.
79. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004: 114 (2 Suppl. 4th Report): 555-576.
80. Parving HH. Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus. Diabetes Care 1991: 14: 260-269.
81. Astrup AS et al. Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 2005: 68: 1250-1257.
82. Wells T et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 2002: 42: 870-880.
83. Strippoli GF et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. Br Med J 2004: 329: 828.
84. Lv J et al. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2012: 12: CD004136.
85. Wu HY et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 2013: 347: f6008.
86. Strippoli GF et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006: 4: CD006257.
87. ACEI Trialist Group (ACE Inhibitors in Diabetic Nephropathy Trialist Group). Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001: 134: 370-379.
88. Izzo JL, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2011: 13: 667-675.
89. Bullo M et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012: 60: 444-450.
90. Tesfaye S et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010: 33: 2285-2293.
91. Breiner A et al. Does the prevailing hypothesis that small-fiber dysfunction precedes large-fiber dysfunction apply to type 1 diabetic patients? Diabetes Care 2014: 37: 1418-1424.
92. Maser RE et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003: 26: 1895-1901.
93. Tang M et al. Autonomic neuropathy in young people with type 1 diabetes: a systematic review. Pediatr Diabetes 2013: 14: 239-248.
94. Jaiswal M et al. Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow-up cohort: a pilot study. Diabetes Care 2013: 36: 3903-3908.
95. Eppens MC et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 2006: 29: 1300-1306.
96. Jaiswal M et al. Reduced heart rate variability among youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care 2013: 36: 157-162.
97. Laing SP et al. Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 2003: 46: 760-765.
98. Mäkimattila S et al. Family histories of type II diabetes and hypertension predict intima-media thickness in patients with type I diabetes. Diabetologia 2002: 45: 711-718.
99. Harrington J et al. Aortic intima media thickness is an early marker of atherosclerosis in children with type 1 diabetes mellitus. J Pediatr 2010: 156: 237-241.
100. Larsen J et al. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes 2002: 51: 2637-2641.
101. Jenkins AJ et al. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care 2003: 26: 810-818.
102. Idzior-Walus B et al. Factors associated with plasma lipids and lipoproteins in type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med 2001: 18: 786-796.
103. Wadwa RP et al. Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care 2005: 28: 1051-1056.
104. Maahs DM et al. Total cholesterol and high-density lipoprotein levels in pediatric subjects with type 1 diabetes mellitus. J Pediatr 2005: 147: 544-546.
105. Guy J et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care 2009: 32: 416-420.
106. Mazanderani AB, Wise SJ, Tildesley HD. Apolipoprotein B levels in adults with type 1 diabetes not receiving lipid-lowering therapy. Clin Biochem 2009: 42: 1218-1221.
107. Collins R et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003: 361: 2005-2016.
108. CTT Collaborators (Cholesterol Treatment Trialists' Collaborators) et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008: 371: 117-125.
109. Wiegman A et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004: 292: 331-337.
110. Stein EA et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999: 281: 137-144.
111. de Jongh S et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002: 106: 2231-2237.
112. Haller MJ et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009: 22: 65-68.
113. Graham DJ et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004: 292: 2585-2590.
114. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004: 25: 543-567.
115. Raev DC. Left ventricular function and specific diabetic complications in other target organs in young insulin-dependent diabetics: an echocardiographic study. Heart Vessels 1994: 9: 121-128.
116. Fraser GE et al. Comparison of echocardiographic variables between type I diabetics and normal controls. Am J Cardiol 1995: 75: 141-145.
117. Regensteiner JG et al. Cardiac dysfunction during exercise in uncomplicated type 2 diabetes. Med Sci Sports Exerc 2009: 41: 977-984.
118. Lalande S, Hofman PL, Baldi JC. Effect of reduced total blood volume on left ventricular volumes and kinetics in type 2 diabetes. Acta Physiol (Oxf) 2010: 199: 23-30.
119. Danielsen R. Factors contributing to left ventricular diastolic dysfunction in long-term type I diabetic subjects. Acta Med Scand 1988: 224: 249-256.
120. Poirier P et al. Impact of left ventricular diastolic dysfunction on maximal treadmill performance in normotensive subjects with well-controlled type 2 diabetes mellitus. Am J Cardiol 2000: 85: 473-477.
121. Gusso S et al. Impaired stroke volume and aerobic capacity in female adolescents with type 1 and type 2 diabetes mellitus. Diabetologia 2008: 51: 1317-1320.
122. Komatsu WR et al. Aerobic exercise capacity in normal adolescents and those with type 1 diabetes mellitus. Pediatr Diabetes 2005: 6: 145-149.
123. Gusso S et al. Diastolic function is reduced in adolescents with type 1 diabetes in response to exercise. Diabetes Care 2012: 35: 2089-2094.
124. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993: 362: 801-809.
125. Meeking DR et al. Endothelial dysfunction in type 2 diabetic subjects with and without microalbuminuria. Diabet Med 1999: 16: 841-847.
126. Elhadd TA et al. Influence of puberty on endothelial dysfunction and oxidative stress in young patients with type 1 diabetes. Diabetes Care 1998: 21: 1990-1996.
127. McLaren M et al. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin Appl Thromb Hemost 1999: 5: 21-24.
128. Cohen R. Dysfunction of the vascular endothelium in diabetes mellitus. Circulation 1993: 87 (Suppl. V): V67-V76.
129. Stehouwer CD et al. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995: 44: 561-564.
130. Urbina EM et al. Prevalence of increased arterial stiffness in children with type 1 diabetes mellitus differs by measurement site and sex: the SEARCH for Diabetes in Youth Study. J Pediatr 2010: 156: 731-737 737.e1.
131. MacKenzie KE et al. Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus. Pediatrics 2006: 118: 242-253.
132. Çiftel M et al. Investigation of endothelial dysfunction and arterial stiffness in children with type 1 diabetes mellitus and the association with diastolic dysfunction. Diab Vasc Dis Res 2014: 11: 19-25.
133. Babar GS et al. Impaired endothelial function in preadolescent children with type 1 diabetes. Diabetes Care 2011: 34: 681-685.
134. Peña AS et al. Hypoglycemia, but not glucose variability, relates to vascular function in children with type 1 diabetes. Diabetes Technol Ther 2012: 14: 457-462.
135. Dye AS et al. Hyperglycemia increases muscle blood flow and alters endothelial function in adolescents with type 1 diabetes. Exp Diabetes Res 2012: 2012: 170380.
136. Peña AS et al. Folate fortification and supplementation do not provide vascular health benefits in type 1 diabetes. J Pediatr 2013: 163: 255-260.
137. Maahs DM et al. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care 2007: 30: 2593-2598.
138. Constantino MI et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 2013: 36: 3863-3869.
139. Wong J et al. Timing is everything: age of onset influences long-term retinopathy risk in type 2 diabetes, independent of traditional risk factors. Diabetes Care 2008: 31: 1985-1990.